\-\ Texto\\:\\ \ \(0\)\
\-\ n\\/a\ \(127\)\
\-\ incomplete\\.\ \(3\)\
\-\ multiple\\ t2\\ hypointense\\ mass\\ lesions\\ throughout\\ the\\ uterus\\,\\ consistent\\ with\\ leiomyomas\\.\\ \ \(0\)\
\-\ \\ \\-subserosal\ \(0\)\
\-\ \\ \\-intramural\\ \ \(0\)\
\-\ \\ \\-sub\\-mucosal\\ pedunculated\\ within\\ the\\ endometrial\\ cavity\\.\\ \ \(0\)\
\-\ transitional\\ zone\\ diffusely\\ thickened\\ with\\ multiple\\ t2\\ hyerintensities\\ throughout\\ the\\ myometrium\\.\ \(0\)\
\-\ multiple\\ t2\\-bright\\ cystic\\ structures\\ within\\ the\\ cervix\\.\ \(0\)\
\-\ adenomyosis\ \(10\)\
\-\ adenomyosis\ \(10\)\
\-\ endometriosis\ \(26\)\
\-\ leiomyomata\ \(3\)\
\-\ nabothian\\ cysts\ \(0\)\
\-\ the\\ patient\\ reported\\ subjective\\ menorrhagia\\ and\\ dysmenorrhea\\.\\ \\ outside\\ sonofound\\ leiomyomatous\\ uterus\\.\\ \\ interested\\ in\\ uterine\\ artery\\ embolization\\ for\\ relief\\ of\\ her\\ symptoms\\.\ \(0\)\
\-\ the\\ importancce\\ of\\ imaging\\ the\\ uterus\\ prior\\ to\\ performing\\ uterine\\ artery\\ embolization\\ \\(uae\\)\\ is\\ demonstrated\\ in\\ this\\ patient\\ with\\ symptomatology\\ which\\ may\\ be\\ relatable\\ to\\ fibroids\\ or\\ secondary\\ to\\ adenomyosis\\.\\ \\ \\ \\ therapies\\ for\\ adenomyosis\\ include\\ hormonal\\ and\\ hysterectomy\\.\\ \\ uae\\ may\\ be\\ curative\\ for\\ patient\\ with\\ simple\\ fibroid\\ uterus\\ whereas\\ this\\ patient\\ should\\ understand\\ the\\ risk\\ of\\ a\\ nontherapeutic\\ result\\ after\\ uae\\ secondary\\ to\\ unresolved\\ adenomyosis\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ adenomyosis\\:\\ 0\\.48301399501904735\ \(0\)\
\-\ uae\\:\\ 0\\.34841732740916465\ \(0\)\
\-\ uterus\\:\\ 0\\.26664970107847785\ \(0\)\
\-\ uterine\\:\\ 0\\.14194624315729606\ \(0\)\
\-\ embolization\\:\\ 0\\.13247209261216358\ \(0\)\
\-\ t2\\:\\ 0\\.13117540476077086\ \(0\)\
\-\ hyerintensities\\:\\ 0\\.12154120410385615\ \(0\)\
\-\ sonofound\\:\\ 0\\.12154120410385615\ \(0\)\
\-\ leiomyomatous\\:\\ 0\\.12154120410385615\ \(0\)\
\-\ importancce\\:\\ 0\\.12154120410385615\ \(0\)\
\-\ relatable\\:\\ 0\\.12154120410385615\ \(0\)\
\-\ nontherapeutic\\:\\ 0\\.12154120410385615\ \(0\)\
\-\ the\\:\\ 0\\.12131868832839124\ \(0\)\
\-\ throughout\\:\\ 0\\.11178878119147616\ \(0\)\
\-\ multiple\\:\\ 0\\.11152036672981382\ \(0\)\
\-\ dysmenorrhea\\:\\ 0\\.1069041667925489\ \(0\)\
\-\ unresolved\\:\\ 0\\.1069041667925489\ \(0\)\
\-\ understand\\:\\ 0\\.10485038560379999\ \(0\)\
\-\ leiomyomas\\:\\ 0\\.10150207182508096\ \(0\)\
\-\ myometrium\\:\\ 0\\.10150207182508096\ \(0\)\
\-\ interested\\:\\ 0\\.1000983320210307\ \(0\)\
\-\ patient\\:\\ 0\\.09887647484842685\ \(0\)\
\-\ menorrhagia\\:\\ 0\\.09882849490712532\ \(0\)\
\-\ artery\\:\\ 0\\.09440263374608336\ \(0\)\
\-\ hormonal\\:\\ 0\\.09383637707233822\ \(0\)\
\-\ secondary\\:\\ 0\\.0900947214695051\ \(0\)\
\-\ therapies\\:\\ 0\\.08900131259472396\ \(0\)\
\-\ curative\\:\\ 0\\.08900131259472396\ \(0\)\
\-\ cervix\\:\\ 0\\.08843428210487027\ \(0\)\
\-\ hysterectomy\\:\\ 0\\.08843428210487027\ \(0\)\
\-\ subjective\\:\\ 0\\.08789040228204456\ \(0\)\
\-\ symptomatology\\:\\ 0\\.08638050091612136\ \(0\)\
\-\ fibroids\\:\\ 0\\.0859129720502252\ \(0\)\
\-\ performing\\:\\ 0\\.08546129470972344\ \(0\)\
\-\ pedunculated\\:\\ 0\\.08502442916121122\ \(0\)\
\-\ fibroid\\:\\ 0\\.08340751352097453\ \(0\)\
\-\ transitional\\:\\ 0\\.08196576169250222\ \(0\)\
\-\ whereas\\:\\ 0\\.08066490429561421\ \(0\)\
\-\ endometrial\\:\\ 0\\.0776300921699344\ \(0\)\
\-\ may\\:\\ 0\\.07649160752488696\ \(0\)\
\-\ to\\:\\ 0\\.07599981483560399\ \(0\)\
\-\ incomplete\\:\\ 0\\.07455877808848432\ \(0\)\
\-\ zone\\:\\ 0\\.07343220262935314\ \(0\)\
\-\ relief\\:\\ 0\\.07127593473891795\ \(0\)\
\-\ diffusely\\:\\ 0\\.07067703815991398\ \(0\)\
\-\ within\\:\\ 0\\.07000689235970071\ \(0\)\
\-\ for\\:\\ 0\\.06910542478258715\ \(0\)\
\-\ simple\\:\\ 0\\.06877047620966727\ \(0\)\
\-\ hypointense\\:\\ 0\\.06688084336655516\ \(0\)\
\-\ thickened\\:\\ 0\\.06410754139076764\ \(0\)\
\-\ cavity\\:\\ 0\\.06274858551299262\ \(0\)\
\-\ be\\:\\ 0\\.061660657623507045\ \(0\)\
\-\ outside\\:\\ 0\\.06100995397104124\ \(0\)\
\-\ with\\:\\ 0\\.0595273232500317\ \(0\)\
\-\ cysts\\:\\ 0\\.0575909598911592\ \(0\)\
\-\ structures\\:\\ 0\\.057106426293506846\ \(0\)\
\-\ result\\:\\ 0\\.05689660769698096\ \(0\)\
\-\ reported\\:\\ 0\\.05473914345171872\ \(0\)\
\-\ risk\\:\\ 0\\.05430370582298948\ \(0\)\
\-\ this\\:\\ 0\\.05223022042760575\ \(0\)\
\-\ should\\:\\ 0\\.04959026403658999\ \(0\)\
\-\ her\\:\\ 0\\.04748074610628279\ \(0\)\
\-\ demonstrated\\:\\ 0\\.046707808397635095\ \(0\)\
\-\ cystic\\:\\ 0\\.045772462630787006\ \(0\)\
\-\ include\\:\\ 0\\.04521955318679401\ \(0\)\
\-\ of\\:\\ 0\\.04461883269562022\ \(0\)\
\-\ lesions\\:\\ 0\\.043647898729911414\ \(0\)\
\-\ prior\\:\\ 0\\.042522364024248895\ \(0\)\
\-\ symptoms\\:\\ 0\\.04158312025987582\ \(0\)\
\-\ consistent\\:\\ 0\\.041209168040146044\ \(0\)\
\-\ imaging\\:\\ 0\\.039940788527633976\ \(0\)\
\-\ in\\:\\ 0\\.03781287195219208\ \(0\)\
\-\ after\\:\\ 0\\.03686904572333792\ \(0\)\
\-\ which\\:\\ 0\\.03455814349868942\ \(0\)\
\-\ and\\:\\ 0\\.03140910933464669\ \(0\)\
\-\ mass\\:\\ 0\\.02903012853045412\ \(0\)\
\-\ or\\:\\ 0\\.02643919003772119\ \(0\)\
\-\ is\\:\\ 0\\.02081322916976723\ \(0\)\
